5 results about "Inhibitory molecules" patented technology

The present disclosure relates to a cell-based assay for determining in vitro tumor killing activity of immune cells expressing a chimeric antigen. The present disclosure provides an in vitro method for determining the potency (e.g., cytotoxicity) of immune cells expressing a chimeric antigen receptor (CAR) molecule. In a test sample, the CAR-expressing immune cells are incubated with target cells that express an antigen that interacts with the CAR. In a control sample, the CAR-expressing immune cells are incubated with the target cells and an inhibitory molecule that prevents the interaction between the CAR and the target cells. The amount of target cell death is determined in both the test sample and the control sample and compared.

This invention belongs to the field of biomedicine and discloses the application of palmitoyltransferase ZDHHC21 in the preparation of drugs for treating breast cancer. This invention demonstrates that ZDHHC21 knockdown upregulates RIPK1 expression, which is related to signal feedback induced by CD82 palmitoylation deficiency. Depalmitoylated CD82 competitively binds to RIPK1 inhibitory molecules, thereby releasing the regulation of RIPK1, promoting the interaction and phosphorylation activation of RIPK1 and RIPK3, and subsequently upregulating MLKL expression and inducing its activation. Downstream activation of Caspase-3 ultimately initiates necroptosis. A specific regulatory axis of "ZDHHC21–CD82–pan-apoptosis" is established. This provides a potential novel therapeutic target for triple-negative breast cancer and offers a theoretical and experimental basis for therapeutic strategies targeting tumor cell death. Further research can explore the role of this regulatory axis in vivo, providing support for clinical translation.

This invention discloses a near-infrared II photothermal therapeutic agent, its preparation method, and its application, belonging to the field of optical diagnostics and treatment technology. To address the problems of insufficient light absorption, fluorescence quenching, and inadequate molecular structure optimization in existing photothermal therapeutic agents, this invention proposes a molecular design strategy of "central plane + peripheral twisting," developing a novel NIR-II photothermal therapeutic agent, 4TPE-TB, which is a near-infrared II photothermal therapeutic agent. This invention enhances the light absorption capacity of the near-infrared II photothermal therapeutic agent by strengthening the conjugation of the molecular core, and utilizes the peripheral twisted structure to suppress intermolecular stacking, significantly improving photothermal conversion efficiency and fluorescence performance, thereby achieving a comprehensive improvement in the therapeutic agent's performance.

The application discloses an assembly synergistic near-infrared two-region nanoparticle based on an electron-rich polymer and a preparation method and application thereof, and belongs to the technical field of precise optical diagnosis and treatment of major diseases such as tumors, and proposes an assembly synergistic strategy, takes an electron-rich block polymer as a carrier, forms an intermolecular electron donor-electron acceptor unit between the carrier and a near-infrared two-region molecule, reduces the singlet and triplet energy level difference of the molecule, promotes inter-gap crossing, effectively inhibits molecular vibration, and thus improves the diagnosis and treatment performance. Compared with a traditional performance optimization method at the molecular level, the application adopts a simple and easy self-assembly strategy, successfully overcomes the problems of low active oxygen yield and low fluorescence quantum yield of the near-infrared two-region optical diagnosis and treatment material, can provide a new and effective means for the precise diagnosis and treatment of major diseases such as tumors, and has a wide application prospect.